A combination of Merck’s Keytruda and Pfizer’s Padcev could offer a chemotherapy-free treatment alternative for patients with ...

Many breast cancer drugs block estrogen receptors inside cancer cells. Blocking the receptors early in disease progression staves off metastasis. But most patients with advanced disease eventually ...

Thanks to modern therapies, a cancer diagnosis is no longer an automatic death sentence. But many patients still suffer from unwanted side effects and limited efficacy. In a recent Bioconjugate ...

Ono Pharmaceutical subsidiary Deciphera Pharmaceuticals has dropped an early-stage candidate for advanced cancers from its ...

CAMBRIDGE, England--(BUSINESS WIRE)--Crescendo Biologics Ltd (Crescendo), the developer of novel, targeted, T cell enhancing therapeutics, and Cancer Research UK, the world’s largest independent ...

In this week’s edition of InnovationRx, we look at cheaper biologic drugs, Novo Nordisk’s $2 billion next-gen obesity drug deal, new ways of fighting cancer, and more.

A leading oncologist proposes classifying metastatic cancer by molecular alterations rather than organ origin, arguing that the shift could accelerate drug access.

This activity was supported by Contract No. 200-2011-38807 (Task Order No. 0051) and Contract No. HHSN263201200074I (Task Order No. HHSN26300052) with the Centers for Disease Control and Prevention ...

The U.S. Food and Drug Administration has approved a new treatment for advanced breast cancer. Drugmaker Eli Lilly announced Sept. 25 the approval of Inluriyo, an oral estrogen receptor antagonist, to ...

The continuous movement of the vocal cords weakens and eventually stops as laryngeal cancer progresses. Researchers have, for ...

NCI has played, and should continue to play, an important role in the development of new cancer therapeutics. That role has changed and will continue to evolve as the basic science underlying cancer ...

A patient has died in a mid-stage study of MacroGenics’ bispecific antibody lorigerlimab in gynecologic cancers, prompting ...